• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

byNeel MistryandTeddy Guo
May 24, 2022
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. 5-year progression-free status was greatest in group 3 (triple therapy) and lowest in group 1 (pelvic bed radiotherapy alone).

2. Grade 2 or greater toxicities were more common in treatment group 3 within the first 3-months of treatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Prostate-specific antigen (PSA) is a marker used to assess for progression of prostate cancer following prostatectomy. Existing research suggests that prostate bed radiotherapy (PBRT) can significantly reduce failure rates. However, the effect of other modalities, including androgen deprivation therapy (ADT) and pelvic lymph node radiotherapy (PLNRT) on prostate cancer is not well known. This randomized controlled trial aimed to compare the safety and efficacy of PBRT alone (group one), PBRT plus short-term ADT (group two), or PBRT plus short-term ADT and PLNRT (group three). The primary outcome was progression-free status at five years, while key secondary outcomes included grade two or three adverse events and castration-resistant disease. According to study results, the proportion of patients achieving progression-free status was significantly greater in group three compared to group one. However, patients in group 3 experienced more acute toxicities within the first three months. This study was strengthened by a large sample size with patients from multiple treatment centers around the world, adding to its generalizability.

Click to read the study in The Lancet

Relevant Reading: Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

In-depth [randomized-controlled trial]: Between Mar 31, 2008, and Mar 30, 2015, 1792 men were assessed for eligibility across 283 radiation oncology treatment centres in the USA, Canada, and Israel. Included were those ≥ 18 years of age with a PSA level of 0.1-2.0 ng/mL, uninvolved lymph nodes and a Gleason score ≤ 9. Altogether, 1716 patients (564 in PBRT alone [group 1], 578 in PBRT plus short-term ADT [group 2], and 574 in PLNRT plus PBRT plus short-term ADT [group 3]) were included in the intention-to-treat analysis. The primary outcome of 5-year freedom from progression was greater in group 3 (87.4%, 95% confidence interval [CI] 84.7-90.2) compared to group 2 (81.3%, 95% CI 78.0-84.6; p=0.0027) and group 1 (70.9%, 95% CI 67.0-74.9; p<0.0001). There were significantly more grade 2 or worse acute adverse events in group 3 (44%) than in group 2 (36%, p=0.0034) or group 1 (18%, p<0.0001). Overall, findings from this study suggest that addition of PBRT with short-term ADT may significantly reduce progression, and improve clinical outcomes, in patients with prostatectomy.

RELATED REPORTS

Plant-based diets may be associated with lower risk of aggressive prostate cancer

Wellness Check: Nutrition

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: androgen deprivation therapy (ADT)pelvic lymph node radiotherapyprostateprostate bed radiotherapyprostate cancerprostate specific antigen (PSA)prostatectomyradiotherapysalvage radiotherapy
Previous Post

Operating the day after performing surgery the previous night not associated with adverse patient outcomes

Next Post

Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia

RelatedReports

Vegetarian diet may lower incidence of colorectal cancer
Lifestyle

Plant-based diets may be associated with lower risk of aggressive prostate cancer

January 27, 2023
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Wellness Check: Nutrition

January 26, 2023
#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer
StudyGraphics

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

January 4, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 2

November 22, 2022
Next Post
Diffusion tensor imaging may aid in Parkinson’s diagnosis

Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia

FDA-approved weight loss medications associated with weight loss at one year

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Wellness Check: Sleep

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options